Its expression is suggested to be a predictive biomarker of tumour aggressiveness.89 Galectin-3 expression has been investigated in 12 invasive prolactinomas and 24 non-invasive prolactinomas, and no significant difference was observed; a positive result for galectin-3 was observed in 45.5% of invasive tumours and 54.5% of non-invasive tumours.28 An association was observed between galectin-3 expression and persistence of hyperprolactinaemia. Here, LGALS3 is linked to neoplasm.